Inventor · disambiguated record
Douglas Macdonald
Also filed as: MACDONALD DOUGLAS · MACDONALD DOUGLAS J L · MACDONALD DOUGLAS JAMES
39 granted patents·13 pending applications·1,099 citations·filing 1978–2025
98Inventor score
Top patents by PatentIndex Score
52 records- 0198US9550837B2Therapeutic uses of anti-PCSK9 antibodiesREGENERON PHARMA·Filed 2015·Granted Jan 24, 2017·31 cites·10 claims
- 0298US8501184B2High affinity human antibodies to PCSK9SLEEMAN MARK W·Filed 2010·Granted Aug 6, 2013·76 cites·3 claims
- 0398US8357371B2Methods for treating hypercholesterolemia using antibodies to PCSK9REGENERON PHARMA·Filed 2011·Granted Jan 22, 2013·89 cites·16 claims
- 0498US8062640B2High affinity human antibodies to PCSK9SLEEMAN MARK W·Filed 2009·Granted Nov 22, 2011·237 cites·3 claims
- 0597US8586713B2Readily isolated bispecific antibodies with native immunoglobulin formatDAVIS SAMUEL·Filed 2010·Granted Nov 19, 2013·422 cites·8 claims
- 0696US12269897B2Anti-PCSK9 antibodiesREGENERON PHARMA·Filed 2023·Granted Apr 8, 2025·1 cites·12 claims
- 0796US10941210B2Anti-PCSK9 antibodiesREGENERON PHARMA·Filed 2018·Granted Mar 9, 2021·6 cites·8 claims
- 0896US10023654B2Anti-PCSK9 antibodiesREGENERON PHARMA·Filed 2016·Granted Jul 17, 2018·16 cites·18 claims
- 0994US9724411B2Methods for treating hypercholesterolemia and reducing LDL-C using antibodies to PCSK9REGENERON PHARMA·Filed 2013·Granted Aug 8, 2017·15 cites·32 claims
- 1094US9447173B2Human antibodies to respiratory syncytial virus F protein and methods of use thereofREGENERON PHARMA·Filed 2014·Granted Sep 20, 2016·37 cites·46 claims
- 1193US11142578B2Anti-MET antibodies, bispecific antigen binding molecules that bind MET, and methods of use thereofREGENERON PHARMA·Filed 2017·Granted Oct 12, 2021·6 cites·26 claims
- 1293US9475875B2Anti-EGFRvIII antibodies and uses thereofREGENERON PHARMA·Filed 2015·Granted Oct 25, 2016·14 cites·9 claims
- 1391US10738124B2Anti-EGFRvIII antibodies and uses thereofREGENERON PHARMA·Filed 2018·Granted Aug 11, 2020·3 cites·27 claims
- 1491US10125188B2Human antibodies to respiratory syncytial virus F protein and methods of use thereofREGENERON PHARMA·Filed 2016·Granted Nov 13, 2018·6 cites·26 claims
- 1591US8889716B2Transglutaminase TG2 inhibitors, pharmaceutical compositions, and methods of use thereofPRIME MICHAEL·Filed 2012·Granted Nov 18, 2014·34 cites·14 claims
- 1691US8791244B2Anti-ErbB3 antibodies and uses thereofREGENERON PHARMA·Filed 2012·Granted Jul 29, 2014·12 cites·8 claims
- 1790US11168111B2Readily isolated bispecific antibodies with native immunoglobulin formatREGENERON PHARMA·Filed 2018·Granted Nov 9, 2021·3 cites·24 claims
- 1890US10806780B2Anti-human papillomavirus (HPV) antigen-binding proteins and methods of use thereofREGENERON PHARMA·Filed 2018·Granted Oct 20, 2020·4 cites·17 claims
- 1989US9982013B2Readily isolated bispecific antibodies with native immunoglobulin formatREGENERON PHARMA·Filed 2016·Granted May 29, 2018·3 cites·22 claims
- 2089US9309326B2Readily isolated bispecific antibodies with native immunoglobulin formatREGENERON PHARMA·Filed 2013·Granted Apr 12, 2016·5 cites·19 claims
- 2187US9273143B2Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibodyREGENERON PHARMA·Filed 2013·Granted Mar 1, 2016·6 cites·24 claims
- 2286US10632194B2Anti-ErbB3 antibodies and uses thereofREGENERON PHARMA·Filed 2017·Granted Apr 28, 2020·2 cites·8 claims
- 2386US9827310B2Anti-ErbB3 antibodies and uses thereofREGENERON PHARMA·Filed 2016·Granted Nov 28, 2017·4 cites·12 claims
- 2485US9284380B2Anti-ErbB3 antibodies and uses thereofREGENERON PHARMA·Filed 2014·Granted Mar 15, 2016·5 cites·23 claims
- 2584US11559576B2Anti-human papillomavirus (HPV) antigen-binding proteins and methods of use thereofREGENERON PHARMA·Filed 2020·Granted Jan 24, 2023·1 cites·23 claims
- 2683US2025064913A1Anti-human papillomavirus (hpv) antigen-binding proteins and methods of use thereofREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 2781US2022389055A1Readily Isolated Bispecific Antibodies with Native Immunoglobulin FormatREGENERON PHARMA·Filed 2022·Application pending·0 cites
- 2880US12115216B2Anti-human papillomavirus (HPV) antigen-binding proteins and methods of use thereofREGENERON PHARMA·Filed 2022·Granted Oct 15, 2024·0 cites·19 claims
- 2979US12157758B2Readily isolated bispecific antibodies with native immunoglobulin formatREGENERON PHARMA·Filed 2021·Granted Dec 3, 2024·0 cites·24 claims
- 3079US2025154286A1Anti-pcsk9 antibodiesREGENERON PHARMA·Filed 2025·Application pending·0 cites
- 3176US9116159B2VEGF-A121 assayREGENERON PHARMA·Filed 2013·Granted Aug 25, 2015·2 cites·15 claims
- 3276US2025250342A2Anti-met antibodies, bispecific antigen binding molecules that bind met, and methods of use thereofREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 3375US10047160B2Anti-EGFRvIII antibodies and uses thereofREGENERON PHARMA·Filed 2016·Granted Aug 14, 2018·1 cites·13 claims
- 3472US11771762B2Anti-ErbB3 antibodies and uses thereofREGENERON PHARMA·Filed 2020·Granted Oct 3, 2023·0 cites·19 claims
- 3572US11608380B2Anti-EGFRvIII antibodies and uses thereofREGENERON PHARMA·Filed 2020·Granted Mar 21, 2023·0 cites·11 claims
- 3670US4275934AAnti-lock brake devicesMCDONALD DOUGLAS J L·Filed 1978·Granted Jun 30, 1981·12 cites·7 claims
- 3769US8946197B2Transglutaminase TG2 inhibitors, pharmaceutical compositions, and methods of use thereofDOMINGUEZ CELIA·Filed 2010·Granted Feb 3, 2015·1 cites·50 claims
- 3866US6183026B1End effectorGASONICS INTERNAT CORP·Filed 1999·Granted Feb 6, 2001·40 cites·33 claims
- 3964US2013085266A1ANTI-PCSK9 ANTIBODIES WITH pH-DEPENDENT BINDING CHARACTERISTICSREGENERON PHARMA·Filed 2012·Application pending·0 cites
- 4062US8787533B2System and method for placing a phone call through a selected telecommunications networkMACDONALD DOUGLAS JAMES·Filed 2010·Granted Jul 22, 2014·2 cites·20 claims
- 4162US2013064834A1Methods for treating hypercholesterolemia using antibodies to pcsk9REGENERON PHARMA·Filed 2012·Application pending·0 cites
- 4257US2017296657A1Methods for Treating Hypercholesterolemia and Reducing LDL-C Using Antibodies to PCSK9REGENERON PHARMA·Filed 2017·Application pending·0 cites
- 4355US9459263B2VEGF-A121 assayREGENERON PHARMA·Filed 2015·Granted Oct 4, 2016·0 cites·17 claims
- 4454US2022409732A1Peptide-mhc ii protein constructs and uses thereofREGENERON PHARMA·Filed 2020·Application pending·0 cites
- 4554US2019031741A1Human Antibodies to Respiratory Syncytial Virus F Protein and Methods of Use ThereofREGENERON PHARMA·Filed 2018·Application pending·0 cites
- 4651US2008044390A1Methods and compositions for the treatment of neurodegenerative disordersJIN XIAOWEI·Filed 2007·Application pending·0 cites
- 4750US2018355038A1Optimized Anti-CD3 Bispecific Antibodies and Uses ThereofREGENERON PHARMA·Filed 2016·Application pending·0 cites
- 4849US7519801B2Post-install configuration of modules during startup of a modular application platformIBM·Filed 2003·Granted Apr 14, 2009·3 cites·12 claims
- 4947US8053458B2Dipyrazole compounds and their use as central nervous system agentsAVENTIS PHARMA INC·Filed 2007·Granted Nov 8, 2011·0 cites·16 claims
- 5044US9751932B2Anti-big-endothelin-1 (big-ET-1) antibodies and uses thereofREGENERON PHARMA·Filed 2013·Granted Sep 5, 2017·0 cites·20 claims
Showing the top 50 of 52 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Douglas Macdonald files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →